ArticlePituitary2026
Decision-making and impulsivity in cabergoline-treated prolactinoma: findings from Iowa Gambling, Go/No-Go, and barratt scales.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis on impulse-control disorders in patients with pituitary adenomas exposed to dopamine agonists.Frontiers in endocrinology · 2026Pooled it
- Help-we need a psychiatrist!Pituitary · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess impulsivity, decision-making performance and inhibitory control in prolactinoma patients treated with dopamine agonists (DA), and to compare these parameters with healthy control(HC) subjects.
methodsA total of 34 patients with prolactinoma, and 35 HCs were included in the study. All patients and controls were screened using demographic information questionnaire, Barratt Impulsiveness Scale–Short Form (BIS-11-SF), Iowa Gambling Task and Go/No-Go Task. Clinical data of all subjects were collected from their electronic medical records.
resultsCompared with healthy controls, patients with prolactinoma receiving dopamine agonist therapy showed a significantly higher frequency of gambling urges and sexual desire during the preceding four weeks (p = 0.003 for both). In the Go/No-Go Task, a significant between-group difference was observed in commission error rates (p = 0.041). Treatment duration was positively correlated with both the frequency of sexual desire over the past four weeks and the non-planning subscale of the BIS-11-SF (r = 0.364, p = 0.035; r = 0.429, p = 0.011, respectively). Cumulative dopamine agonist dose was positively correlated with the frequency of sexual desire, the frequency of sexual intercourse attempts over the past four weeks, and the non-planning subscale of the BIS-11-SF (r = 0.405, p = 0.018; r = 0.433, p = 0.011; and r = 0.418, p = 0.014, respectively).
conclusionsIn patients with prolactinoma, dopamine agonist treatment is associated with selective alterations in decision-making–related impulsivity and inhibitory control, influenced by treatment duration and cumulative dopamine agonist exposure.
Indexed as
Identifiers
42056354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.